Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel.
Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults with first and second-stage polyneuropathy.
The agreement also involves the commercialisation of givosiran and lumasiran, which are being developed to treat acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1), respectively.
Based in the US, Alnylam Pharmaceuticals is a biopharmaceutical company engaged in developing ribonucleic (RNA) therapeutics for hereditary diseases, while Medison Pharma is an Israel-based healthcare solutions company engaged in providing diagnostic products for neurology, oncology and various infectious diseases.
Novartis has signed an agreement to use Kinaxis’ RapidResponse platform, a Cloud-based software that provides country-specific product expiry monitoring and planning across a company’s global network.
Based in Switzerland, Novartis is a pharmaceutical company engaged in developing a wide range of healthcare products, while Kinaxis is a Canada-based software company focused on developing supply chain management systems.
Acrotech Biopharma has entered a definitive agreement with Spectrum Pharmaceuticals to buy seven haematology and oncology drugs for up to $300m through its subsidiary Aurobindo Pharma USA.
Acrotech has agreed to make an upfront payment of $160m in cash and up to $140m in milestone payments.
The drugs being purchased under the deal include usilev (levoleucovorin), Zevalin (ibritumomab tiuxetan), Evomela (melphalan) for injection, Khapzory (levoleucovorin), Marqibo (vinCRIStine sulfate Liposome injection), Folotyn (pralatrexate injection) and Beleodaq (belinostat).
The transaction is expected to be closed by March 2019, subject to regulatory approvals.
Acrotech Biopharma is a pharmaceutical company engaged in commercialising innovative proprietary medicines, while Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments.
Both the companies involved in the deal are based in the US.
Luye Pharma has signed an agreement with AstraZeneca to license its cholesterol medicine Xuezhikang capsules in mainland China.
Under the agreement, Luye Pharma will hold the commercial sales rights, registration permits, intellectual property and additional product-related rights to the drug.
The deals will enable the companies to expand the accessibility of Xuezhikang to different countries, including the US and Europe.
Based in the UK, AstraZeneca is a biopharmaceutical company engaged in developing innovative medicines, while Luye Pharma is a China-based speciality pharmaceutical company focused on developing pharmaceutical products.
GlaxoSmithKline (GSK) has completed an acquisition of Tesaro for $5.1bn.
Completed through GSK’s indirect wholly owned subsidiary Adriatic Acquisition Corporation, the acquisition is expected to expand the company’s oncology pipeline.
Based in the UK, GSK is a pharmaceutical company engaged in developing and discovering innovative healthcare products, while Tesaro is a US-based biopharmaceutical focused on oncology drug development.